Pharma Giant AstraZeneca Takes China Probes
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
CEO of AstraZeneca Pascal Soriot (Justin Tallis/PA) PA Wire In its third quarter update on Tuesday, chief executive ...
“Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of ...
“Our multibillion-dollar investment reflects the attractiveness of the business environment together with the quality of ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...
Additionally, it will also increase its cell therapy manufacturing capacity on the West and East Coasts. Pascal Soriot, CEO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback